RxDoctor Payments Data

Jussep Fombellida Martinez, APRN

Family · Orlando, FLNPI 1831716067

Payments from drug & device makers

$866in general payments, 2019–2025

Across 44 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$268
  • AbbVie$161
  • Bayer$86
  • Amgen$67
  • Pfizer$59
  • Phathom Pharmaceuticals, Inc.$45
  • plus $179 from 8 others

What the payments were for

  • Food & beverage$866100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$866 in reported general payments places this provider in the 65th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$17,675
Medicare patients
33
Services billed
174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide84$118,287
JardianceEmpagliflozin79$104,579
BiktarvyBictegrav/Emtricit/Tenofov Ala14$58,779
EliquisApixaban39$53,077
FarxigaDapagliflozin Propanediol42$39,937
TrulicityDulaglutide24$33,316
JanuviaSitagliptin Phosphate18$27,935
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$13,635
XareltoRivaroxaban17$13,144
LantusInsulin Glargine,hum.Rec.Anlog74$11,133
LinzessLinaclotide18$10,699
SymbicortBudesonide/Formoterol Fumarate35$10,597
Lantus SolostarInsulin Glargine,hum.Rec.Anlog47$8,045
Humalog Kwikpen U-100Insulin Lispro17$5,615
Atorvastatin Calcium460$4,846

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$268$120,73899 claims
PfizerEliquis$59$53,07739 claims
Lilly USA, LLCTrulicity$36$33,31624 claims
Johnson & JohnsonXarelto$16$13,14417 claims
AbbVieLinzess$161$10,69918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 14,618 family providers in Florida.

Other family in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →